This study was presented in part as an abstract at the 2nd Annual ASTRO Multidisciplinary Head and Neck Cancer Symposium in Chandler, Arizona, February 25–27, 2010.
Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature†
Article first published online: 4 NOV 2010
Copyright © 2010 Wiley Periodicals, Inc.
Head & Neck
Volume 34, Issue 5, pages 753–757, May 2012
How to Cite
Setton, J., Wolden, S., Caria, N., Lee, N. (2012), Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. Head Neck, 34: 753–757. doi: 10.1002/hed.21608
- Issue published online: 6 APR 2012
- Article first published online: 4 NOV 2010
- Manuscript Accepted: 12 AUG 2010
- nasopharyngeal carcinoma;
- head-and-neck cancer
To review the treatment outcomes of patients presenting to Memorial Sloan-Kettering Cancer Center with metastatic nasopharyngeal carcinoma.
From April 1999 to April 2008, 5 patients with histologically confirmed nasopharyngeal carcinoma initially presenting with distant metastasis underwent chemotherapy and definitive radiation therapy at our institution. Each patient received platinum-based chemotherapy concurrently with definitive radiotherapy to the primary region and subsequent consolidation radiotherapy to distant metastases. In addition, 2 patients received induction chemotherapy (cisplatin, fluorouracil), and 3 others received adjuvant chemotherapy (cisplatin or carboplatin, fluorouracil).
Of 5 patients initially presenting to our institution with M1 disease, 2 have no evidence of disease as of their last follow-up (29 and 91 months). The remaining 3 patients had progression of disease within 12 months of the start of treatment.
Long-term disease-free survival is possible in a select group of patients with M1 disease at presentation treated with platinum-based chemotherapy and definitive radiotherapy © 2010 Wiley Periodicals, Inc. Head Neck, 2012